Priming with Dendritic Cells Can Generate Strong Cytotoxic T Cell Responses to Chronic Myelogenous Leukemia Cells In Vitro
- 1 April 2004
- journal article
- other
- Published by Mary Ann Liebert Inc in Stem Cells and Development
- Vol. 13 (2) , 211-221
- https://doi.org/10.1089/154732804323046828
Abstract
Dendritic cells (DC) are antigen-presenting cells that can elicit potent antigen-specific responses. Since the development of techniques to cultivate these cells from peripheral blood, there has been a great deal of interest in their use in immunotherapeutic strategies. Here we show that morphologically, phenotypically, and functionally characteristic DC can be generated in vitro from peripheral blood mononuclear cells (PBMC) isolated from frozen apheresis product (AP) of cancer patients. These DC, when pulsed with whole-tumor lysate, protein, or RNA from a chronic myelogenous leukemia (CML) cell line, can induce anti-CML specific cytotoxicity in vitro by autologous cytotoxic T lymphocytes (CTL). RNA and protein-pulsed DC were more effective than lysate-pulsed DC at inducing cytotoxicity at low effector:target (E:T) ratios. These results were comparable to those obtained when fresh healthy peripheral blood was used as the source of PBMC, indicating that neither the malignant state of the patient nor the storage period detrimentally affected the generation or functionality of DC. CML cells were found to increase their level of MHC class I expression after exposure to CTL and pulsed DC thereby becoming better targets. These investigations lend support for the utilization of DC to generate anti-tumor responses in CML.Keywords
This publication has 35 references indexed in Scilit:
- Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cellsLeukemia, 2003
- Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migrationBlood, 2003
- The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemiaHematological Oncology, 2003
- Imatinib mesylate (Gleevec(R)/Glivec(R)): A new therapy for chronic myeloid leukemia and other malignanciesDrugs of Today, 2002
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- Analysis of a Chronic Myelogenous Leukemia Patient Vaccinated with Leukemic Dendritic Cells Following Autologous Peripheral Blood Stem Cell TransplantationJapanese Journal of Cancer Research, 1999
- TrueLeukemia, 1999
- Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNANature Biotechnology, 1998
- Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytesEuropean Journal of Immunology, 1997
- Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivoEuropean Journal of Immunology, 1994